Skip to content
Helping patients reclaim a life of possibility
Menu
  • About us
  • Contact us
logo MPE
  • Myeloma and AL Amyloidosis
    • About Myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month 2025
        • MPE Masterclass
        • Scholarship programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
  • Myeloma and AL Amyloidosis
    • About Myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month 2025
        • MPE Masterclass
        • Scholarship programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
MorineWebsite

MORINE MAGURI

Morine joined MPE as Project Officer in December 2021.

Morine holds a Bachelor’s Degree in Development Studies from Midlands State University in Zimbabwe. She previously worked for an NGO that focused on advocating for people with terminal and stigmatised diseases such as HIV and was also involved in providing counselling, education and support to people living in vulnerable communities.

In 2018 she moved to Germany, and since then, she has gained experience in nursing procedures related to treatment plans, medication schedules and patient assessments. Morine speaks English, German and Shona.

Recent Posts

Myeloma and infection: clinical and lived perspectives webinar

July 30, 2025

Myeloma Patients Europe (MPE) will host a webinar on “Myeloma and infection: clinical and lived perspectives” on Thursday, 11th September 2025 from 17:00 – 18:00 CEST. Aimed at myeloma patients, carers…

Read more

The European Commission grants final authorisation for isatuximab (Sarclisa®) for transplant eligible newly diagnosed myeloma patients

July 25, 2025

The European Commission (EC) has approved isatuximab (Sarclisa®) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction (i.e., initial) treatment of newly diagnosed myeloma patients (NDMM) who are…

Read more

The European Commission grants final authorisation for belantamab mafodotin (Blenrep®) combinations for relapsed/refractory myeloma patients

July 25, 2025

Two belantamab mafodotin (Blenrep®) combinations, with bortezomib and dexamethasone or pomalidomide and dexamethasone, are now authorised for use in the European Union. The decision follows an earlier positive recommendation of…

Read more

European Commission approves first treatment for high-risk smouldering myeloma

July 24, 2025

The European Commission (EC) has approved a new indication for daratumumab (Darzalex®) for the treatment of adult patients with smouldering myeloma (SMM) at high-risk of developing myeloma. This follows a…

Read more

New guidelines for the treatment and the management of myeloma and smouldering myeloma

July 14, 2025

On July 7th, 2025, new clinical management guidelines for myeloma and smouldering myeloma were published in Nature Reviews Clinical Oncology by myeloma experts. These guidelines are written to guide doctors and…

Read more

MPE member spotlight: Multiple Myeloma Ireland

July 8, 2025

On May 23rd, MPE member organisation, Multiple Myeloma Ireland (MMI) successfully hosted its 2025 Patient and Family Information Day at the Ashling Hotel in Dublin. Multiple Myeloma Ireland is the only charitable organisation…

Read more
mpe logo negativo 300x249 1

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2025
  • Contact
  • About us
  • Privacy policy
  • Terms and conditions
  • Cookies Policy
Go to Top
logo MPE
  • About MPE
    • Our members
    • Our board and staff
    • Medical Advisory Committee
    • Our Strategic Goals
    • Our funding
    • Get involved in MPE activities
    • Become a member
  • Contact us
  • Myeloma and AL Amyloidosis
    • About Myeloma
    • About AL amyloidosis
  • What we do
    • Member and patient community programmes
      • Myeloma Awareness Month 2025
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • News
  • European Myeloma Day

PopUp

  • This field is for validation purposes and should be left unchanged.